2,569 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Avior Wealth Management LLC

Avior Wealth Management LLC acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,569 shares of the biopharmaceutical company’s stock, valued at approximately $101,000.

Other hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its holdings in Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 641 shares during the last quarter. nVerses Capital LLC purchased a new position in Xenon Pharmaceuticals in the 3rd quarter worth approximately $102,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Xenon Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 487 shares during the last quarter. Quarry LP raised its stake in Xenon Pharmaceuticals by 207.7% during the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 2,700 shares during the last quarter. Finally, Vestcor Inc purchased a new stake in Xenon Pharmaceuticals during the 3rd quarter valued at $327,000. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ian Mortimer sold 22,468 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at $1,258,340.40. This trade represents a 41.79 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,383 shares of company stock valued at $2,535,891. Company insiders own 5.52% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on XENE. Raymond James reiterated an “outperform” rating and set a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus price target of $56.00.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $40.00 on Wednesday. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of -14.18 and a beta of 1.20. Xenon Pharmaceuticals Inc. has a one year low of $35.53 and a one year high of $50.99. The business has a fifty day moving average price of $40.23 and a 200-day moving average price of $40.82.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same period in the previous year, the business earned ($0.73) earnings per share. On average, equities research analysts expect that Xenon Pharmaceuticals Inc. will post -3.13 earnings per share for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.